Profile data is unavailable for this security.
About the company
Krebs Biochemicals & Industries Ltd is an India-based company, which is engaged in the business of manufacture of active pharmaceutical ingredients. The Company manufactures bulk active pharmaceutical ingredients, pharmaceutical intermediates, fine chemicals, nutraceuticals utilizing two revenue streams: contract manufacturing for large pharmaceutical and multinational companies, and development of its products for sale in global markets. Its products include Androstenedione, Lovastatin, and Simvastatin. The Company’s pilot or research and development stages products are Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan, and Phenylephrine. The Company has two manufacturing facilities one at Regadichelaka, Nellore District and another one at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.
- Revenue in INR (TTM)230.23m
- Net income in INR-228.62m
- Incorporated1991
- Employees202.00
- LocationKrebs Biochemicals and Industries LtdInwinex Towers, Plot No. 130, 4th FloorRoad No. 2, Regadichelika VillageBanjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 066808040
- Fax+91 4 023540320
- Websitehttp://krebsbiochem.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Drugs and Chemicals Ltd | 1.06bn | 139.06m | 1.13bn | 121.00 | 8.10 | -- | 6.40 | 1.06 | 11.30 | 11.30 | 86.47 | -- | -- | -- | -- | 8,791,298.00 | -- | 13.79 | -- | 16.47 | 58.42 | 43.07 | 13.07 | 14.02 | -- | 137.75 | -- | -- | 5.58 | 12.57 | -7.88 | 22.90 | -4.68 | -- |
| Krebs Biochemicals And Industries Ltd | 230.23m | -228.62m | 1.15bn | 202.00 | -- | -- | -- | 4.98 | -10.60 | -10.60 | 10.68 | -74.60 | -- | -- | -- | 1,139,753.00 | -- | -16.90 | -- | -26.56 | 96.27 | 20.39 | -99.30 | -55.63 | 0.0359 | -2.42 | 3.65 | -- | -14.10 | 5.33 | -36.55 | -- | -17.65 | -- |
| Bal Pharma Ltd | 3.09bn | 81.31m | 1.17bn | 986.00 | 14.69 | -- | 6.37 | 0.3773 | 4.99 | 4.99 | 192.78 | -- | -- | -- | -- | 3,138,557.00 | -- | 1.95 | -- | 5.49 | 47.13 | 43.12 | 2.63 | 1.88 | -- | 1.12 | -- | 30.29 | -10.65 | 12.12 | -2.39 | -- | 29.98 | -- |
| Sotac Pharmaceuticals Ltd | 814.02m | 87.04m | 1.23bn | 67.00 | 14.10 | 2.20 | 8.10 | 1.51 | 7.87 | 7.87 | 73.61 | 50.39 | 0.6818 | 2.86 | 2.67 | 12,149,600.00 | 8.46 | 5.81 | 16.28 | 12.47 | 37.26 | 25.59 | 12.40 | 4.69 | 0.9737 | 2.30 | 0.3854 | -- | -6.59 | 27.66 | 124.25 | 146.89 | 11.66 | -- |
| Alpa Laboratories Limited | 1.14bn | 116.09m | 1.33bn | 453.00 | 11.48 | -- | 9.46 | 1.16 | 5.51 | 5.51 | 53.34 | -- | -- | -- | -- | 2,523,914.00 | -- | 8.59 | -- | 10.61 | 26.16 | 33.75 | 10.15 | 13.40 | -- | -17.25 | -- | -- | 3.41 | 5.52 | 16.25 | 60.11 | 34.92 | -- |
